XORTX Therapeutics Inc

詳細情報 XORTX Therapeutics Inc 企業名

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

企業情報

企業コードXRTX

会社名XORTX Therapeutics Inc

上場日Sep 30, 2015

最高経営責任者「CEO」Dr. Allen W. Davidoff, Ph.D.

従業員数2

証券種類Ordinary Share

決算期末Sep 30

本社所在地3710 - 33rd Street NW

都市CALGARY

証券取引所TSX Venture Exchange (former Canadian Ventures Exchange)

国Canada

郵便番号T2L 2M1

電話番号14034557727

ウェブサイトhttps://www.xortx.com/

企業コードXRTX

上場日Sep 30, 2015

最高経営責任者「CEO」Dr. Allen W. Davidoff, Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. James (Jim) Fairbairn

Chief Financial Officer

6.95K

+314.44%

Mr. Paul J. Van Damme

Independent Director

--

Dr. Stephen Haworth

Chief Medical Officer

--

Mr. William (Bill) Farley

Independent Director

--

Mr. Patrick Treanor

Independent Director

--

Dr. Allen W. Davidoff, Ph.D.

President, Chief Executive Officer, Director

--

Mr. Anthony J. Giovinazzo

Independent Non-Executive Chairman of the Board

--

Ms. Abigail Jenkins

Independent Director

--

Mr. Stacy Evans, M.D.

Chief Business Officer

--

Dr. Raymond Dennis (Ray) Pratt, M.D.

Independent Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. James (Jim) Fairbairn

Chief Financial Officer

6.95K

+314.44%

Mr. Paul J. Van Damme

Independent Director

--

Dr. Stephen Haworth

Chief Medical Officer

--

Mr. William (Bill) Farley

Independent Director

--

Mr. Patrick Treanor

Independent Director

--

Dr. Allen W. Davidoff, Ph.D.

President, Chief Executive Officer, Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Wed, Aug 20

株主統計

種類

株主統計

比率

Davidoff, Allen Warren

2.31%

Citadel Advisors LLC

0.74%

UBS Financial Services, Inc.

0.40%

Giovinazzo (Anthony)

0.18%

Van Damme (Paul Joseph)

0.14%

他の

96.23%

株主統計

比率

Davidoff, Allen Warren

2.31%

Citadel Advisors LLC

0.74%

UBS Financial Services, Inc.

0.40%

Giovinazzo (Anthony)

0.18%

Van Damme (Paul Joseph)

0.14%

他の

96.23%

種類

株主統計

比率

Individual Investor

2.63%

Hedge Fund

0.74%

Investment Advisor

0.40%

Bank and Trust

0.08%

他の

96.16%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

17

129.44K

3.30%

-739.58K

2025Q1

20

127.29K

3.49%

-606.22K

2024Q4

21

385.20K

10.34%

-244.07K

2024Q3

22

287.39K

12.35%

-145.77K

2024Q2

20

276.67K

12.12%

-141.93K

2024Q1

21

272.84K

13.24%

-121.02K

2023Q4

19

553.49K

27.69%

+481.09K

2023Q3

20

176.53K

8.83%

-185.14K

2023Q2

19

179.60K

8.98%

-178.94K

2023Q1

18

180.91K

11.39%

-170.46K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Davidoff, Allen Warren

112.26K

2.96%

+800.00

+0.72%

Jun 23, 2025

Citadel Advisors LLC

--

0%

-12.33K

-100.00%

Sep 30, 2024

UBS Financial Services, Inc.

--

0%

-17.43K

-100.00%

Mar 31, 2025

Giovinazzo (Anthony)

9.63K

0.25%

--

Apr 30, 2025

Van Damme (Paul Joseph)

7.11K

0.19%

--

Apr 30, 2025

National Bank of Canada

174.00

0%

-1.44K

-89.21%

Mar 31, 2025

Clearstead Advisors LLC

277.00

0.01%

--

Mar 31, 2025

Armistice Capital LLC

--

0%

-265.00K

-100.00%

Mar 31, 2025

詳細を見る

0.831USD

XORTX Therapeutics Inc

0.831

概要

企業名

金融

分析